A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To assess the effects and safety of PF-00610355 on patients with chronic obstructive lung disease (COPD)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Salmeterol Xinafoate

Criteria

Inclusion Criteria:

• Post-bronchodilator FEV1/FVC ratio <0.7 and a post-bronchodilator FEV1 of 50-80%.

• Diagnosis of moderate COPD for a minimum of 6 months.

• Stable disease for at least 1 month prior to screening

Exclusion Criteria:

• More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalisation for the treatment of COPD within 3 months of screening or more than twice during the preceding year.

• History of a lower respiratory tract infection or significant disease instability during the month preceding screening or during the time between screening and randomisation.